Amphastar Pharmaceuticals Company Profile (NASDAQ:AMPH)

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals logoAmphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, Cortrosyn, Amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin and porcine insulin. The Company manufactures and sells approximately 20 products. Additionally, the Company is developing a portfolio of approximately 10 generic abbreviated new drug applications (ANDA), over three generic biosimilar and over six injectable and inhalation product candidates.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AMPH
  • CUSIP:
Key Metrics:
  • Previous Close: $18.59
  • 50 Day Moving Average: $19.03
  • 200 Day Moving Average: $16.46
  • 52-Week Range: $10.50 - $21.53
  • Trailing P/E Ratio: 60.03
  • Foreward P/E Ratio: 34.86
  • P/E Growth: 2.04
  • Market Cap: $834.29M
  • Outstanding Shares: 45,121,000
  • Beta: 1.83
  • Net Margins: 5.19%
  • Return on Equity: 4.71%
  • Return on Assets: 3.51%
  • Debt-to-Equity Ratio: 0.10%
  • Current Ratio: 2.76%
  • Quick Ratio: 1.42%
Additional Links:
Companies Related to Amphastar Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Amphastar Pharmaceuticals (NASDAQ:AMPH) (?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $19.80 (7.17% upside)

Analysts' Ratings History for Amphastar Pharmaceuticals (NASDAQ:AMPH)
DateFirmActionRatingPrice TargetDetails
9/7/2016Piper Jaffray Cos.Reiterated RatingOverweight$22.00 -> $23.00View Rating Details
8/9/2016Jefferies GroupBoost Price TargetBuy$16.00 -> $19.00View Rating Details
8/9/2016BMO Capital MarketsReiterated RatingHold$17.00View Rating Details
8/9/2016Needham & Company LLCBoost Price TargetBuy$20.00 -> $22.00View Rating Details
3/15/2016Raymond James Financial Inc.Lower Price Target$23.00 -> $18.00View Rating Details
2/19/2016Wells Fargo & Co.Initiated CoverageOutperformView Rating Details
(Data available from 10/25/2014 forward)


Earnings History for Amphastar Pharmaceuticals (NASDAQ:AMPH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2016Q2$0.01$0.23$62.10 million$68.00 millionViewN/AView Earnings Details
5/9/2016Q1($0.03)$0.12$62.00 million$59.40 millionViewN/AView Earnings Details
3/14/2016Q415($0.04)$0.19$64.48 million$76.90 millionViewN/AView Earnings Details
11/12/2015Q315($0.08)($0.01)$19.49 million$63.90 millionViewListenView Earnings Details
8/12/2015Q215($0.11)($0.09)$19.49 million$53.85 millionViewListenView Earnings Details
5/13/2015Q115($0.17)($0.01)$45.87 million$56.89 millionViewListenView Earnings Details
3/24/2015Q414($0.06)($0.03)$54.90 million$55.90 millionViewN/AView Earnings Details
11/12/2014Q314($0.09)($0.07)$45.89 million$59.70 millionViewN/AView Earnings Details
8/12/2014($0.11)$0.02ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Amphastar Pharmaceuticals (NASDAQ:AMPH)
Current Year EPS Consensus Estimate: $0.22 EPS
Next Year EPS Consensus Estimate: $0.53 EPS


Dividend History for Amphastar Pharmaceuticals (NASDAQ:AMPH)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Amphastar Pharmaceuticals (NASDAQ:AMPH)
Insider Ownership Percentage: 29.30%
Institutional Ownership Percentage: 35.80%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/3/2016Floyd F PetersenDirectorSell400$18.75$7,500.00View SEC Filing  
9/26/2016Jason B ShandellInsiderSell56,996$19.50$1,111,422.00View SEC Filing  
9/20/2016Jack Y ZhangCEOSell444,199$21.03$9,341,504.97View SEC Filing  
9/8/2016Floyd F PetersenDirectorSell3,000$19.05$57,150.00View SEC Filing  
9/1/2016Howard LeeDirectorSell10,381$18.78$194,955.18View SEC Filing  
8/22/2016Jason B ShandellGeneral CounselSell10,000$19.95$199,500.00View SEC Filing  
8/19/2016Diane G GerstEVPSell24,046$19.28$463,606.88View SEC Filing  
8/18/2016Richard K PrinsDirectorSell3,086$19.62$60,547.32View SEC Filing  
8/17/2016Jason B ShandellInsiderSell5,987$18.86$112,914.82View SEC Filing  
8/16/2016Stephen B ShohetDirectorSell48,375$18.24$882,360.00View SEC Filing  
8/15/2016Michael A ZasloffDirectorSell48,375$18.15$878,006.25View SEC Filing  
8/12/2016William J PetersCFOSell1,027$18.19$18,681.13View SEC Filing  
8/11/2016Jason B ShandellPresidentSell5,636$18.01$101,504.36View SEC Filing  
8/11/2016Richard K PrinsDirectorSell13,993$18.03$252,293.79View SEC Filing  
7/18/2016William J PetersCFOSell2,297$17.76$40,794.72View SEC Filing  
6/15/2016Rong ZhouEVPSell1,551$15.85$24,583.35View SEC Filing  
6/13/2016Richard K PrinsDirectorSell7,500$15.94$119,550.00View SEC Filing  
6/9/2016Jason B ShandellPresidentSell9,904$16.43$162,722.72View SEC Filing  
6/2/2016William J PetersCFOSell2,297$16.00$36,752.00View SEC Filing  
5/25/2016Jason B ShandellPresidentSell1,074$15.60$16,754.40View SEC Filing  
5/18/2016Diane G GerstEVPSell1,427$13.97$19,935.19View SEC Filing  
5/17/2016Richard K PrinsDirectorSell3,200$13.56$43,392.00View SEC Filing  
4/19/2016Diane G GerstEVPSell21,244$12.89$273,835.16View SEC Filing  
4/18/2016Diane G GerstEVPSell15,637$12.83$200,622.71View SEC Filing  
3/17/2016Richard K PrinsDirectorSell2,400$11.25$27,000.00View SEC Filing  
12/17/2015Stephen B. ShohetDirectorSell30,770$14.19$436,626.30View SEC Filing  
12/16/2015Howard LeeDirectorSell38,462$14.34$551,545.08View SEC Filing  
12/16/2015Rong ZhouEVPSell772$14.29$11,031.88View SEC Filing  
12/11/2015Jack Y ZhangCEOSell63,300$14.25$902,025.00View SEC Filing  
12/8/2015Jack Y ZhangCEOSell68,117$14.71$1,002,001.07View SEC Filing  
12/3/2015Jack Y ZhangCEOSell38,583$15.45$596,107.35View SEC Filing  
8/18/2015Richard K PrinsDirectorSell9,100$14.66$133,406.00View SEC Filing  
8/17/2015Richard K. PrinsDirectorSell5,400$14.70$79,380.00View SEC Filing  
7/17/2015Michael A ZasloffDirectorSell7,692$17.41$133,917.72View SEC Filing  
6/17/2015Rong ZhouEVPSell1,000$16.48$16,480.00View SEC Filing  
6/15/2015Jack Y ZhangCEOSell45,382$16.29$739,272.78View SEC Filing  
6/12/2015Jack Y ZhangCEOSell160,495$16.23$2,604,833.85View SEC Filing  
6/9/2015Jack Y ZhangCEOSell193,758$16.43$3,183,443.94View SEC Filing  
5/22/2015Richard K PrinsDirectorSell29,452$14.77$435,006.04View SEC Filing  
5/19/2015Richard K PrinsDirectorSell3,000$14.94$44,820.00View SEC Filing  
4/9/2015Marilyn J PurchaseVPSell28,000$15.79$442,120.00View SEC Filing  
4/8/2015Diane G GerstSVPSell10,000$15.79$157,900.00View SEC Filing  
8/25/2014Howard LeeDirectorBuy6,000$10.84$65,040.00View SEC Filing  
8/19/2014Michael A ZasloffDirectorBuy3,500$10.00$35,000.00View SEC Filing  
8/18/2014Richard K PrinsDirectorBuy4,000$10.02$40,080.00View SEC Filing  
8/15/2014Floyd F PetersenDirectorBuy3,200$10.35$33,120.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Amphastar Pharmaceuticals (NASDAQ:AMPH)
News IconSentiment Update on This Dynamic Stock: Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - CSZ News (NASDAQ:AMPH) - October 23 at 3:26 PM
News IconKalmar Investments Inc. DE Invests $3397000 in Amphastar Pharmaceuticals Inc. (AMPH) - DailyQuint (NASDAQ:AMPH) - October 23 at 8:15 AM
News IconAnalysts Projecting Steady Growth for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - CSZ News (NASDAQ:AMPH) - October 20 at 9:23 PM
News IconFlash in the Pan or Long Term Growth Play: Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - CSZ News (NASDAQ:AMPH) - October 20 at 9:23 PM logoETF’s with exposure to Amphastar Pharmaceuticals, Inc. : October 19, 2016 (NASDAQ:AMPH) - October 19 at 4:17 PM
News IconAnalysts Projecting Steady Growth for Amphastar Pharmaceuticals ... - CSZ News (NASDAQ:AMPH) - October 18 at 3:28 PM
News IconPrice Target Watch on Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Recall News (NASDAQ:AMPH) - October 17 at 3:29 PM
News IconInsiders are Scaling Back Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - CSZ News (NASDAQ:AMPH) - October 17 at 3:29 PM
News IconForging Higher Over Past 6-Months, Can It Continue For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - CSZ News (NASDAQ:AMPH) - October 17 at 8:17 AM
News IconAmphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Latest Broker ... - NewsDen (NASDAQ:AMPH) - October 16 at 8:16 AM
News IconThree Dozen States Sue Makers of Opioid Addiction Treatment... (NASDAQ:AMPH) - October 13 at 12:55 PM logoAmphastar Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AMPH-US : October 13, 2016 (NASDAQ:AMPH) - October 13 at 12:55 PM
News IconBOMBSHELL: Hillary Strategist Says Hillary PERSONALLY Deleted Emails And Her Donors Make Money Off Of Heroin Addicts (NASDAQ:AMPH) - October 11 at 8:33 PM
News IconInsiders are Curtailing Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - CSZ News (NASDAQ:AMPH) - October 11 at 3:32 PM
News IconShort Interest Worth Mentioning: Is Buying Amphastar ... - Post News (NASDAQ:AMPH) - October 7 at 3:28 PM
News IconInsider Heat: Reasons for Floyd Petersen's Shares Unload of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH)'s Stock - Thorold News (NASDAQ:AMPH) - October 7 at 3:28 PM
News IconSupreme Court Declines to Review Scope of Section 271(e)(1) Safe-Harbor - JD Supra (press release) (NASDAQ:AMPH) - October 6 at 3:26 PM logoTeva to Divest Actavis Generics' UK & Ireland Operations (NASDAQ:AMPH) - October 6 at 9:15 AM logoAllergan Buys Rights to AstraZeneca's Crohn's Disease Drug - Yahoo Finance (NASDAQ:AMPH) - October 4 at 3:28 PM logoAllergan Buys Rights to AstraZeneca's Crohn's Disease Drug - Yahoo Finance (NASDAQ:AMPH) - October 4 at 3:28 PM logoJustices Won’t Eye Reach Of Hatch-Waxman Safe Harbor (NASDAQ:AMPH) - October 4 at 8:17 AM
News IconSupreme Court Again Refuses to Clarify Scope of Hatch-Waxman Safe Harbor (NASDAQ:AMPH) - October 4 at 8:17 AM
News IconBroker Roundup For Amphastar Pharmaceuticals, Inc. (NASDAQ ... - The De Soto Edge (NASDAQ:AMPH) - October 3 at 3:27 PM
News IconAmphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) – Broker Update - NewsDen (NASDAQ:AMPH) - October 2 at 3:26 PM
News IconWhat are Research Firms Saying About Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)? - Frisco Fastball (NASDAQ:AMPH) - October 1 at 3:24 PM
News IconBroker Roundup For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - The De Soto Edge (NASDAQ:AMPH) - September 29 at 8:16 AM logoInsiders Selling, Short Interest Growing Amphastar Pharmaceuticals ... - Finance Daily (NASDAQ:AMPH) - September 28 at 8:17 AM logoAmphastar Pharmaceuticals Inc (AMPH) CEO & Chief Science Officer Jack Y. Zhang Sold $9. ... - Nasdaq (NASDAQ:AMPH) - September 24 at 8:48 AM logoAmphastar Pharmaceuticals Inc (AMPH) CEO & Chief Science Officer Jack Y. Zhang Sold $9.3 million of Shares (NASDAQ:AMPH) - September 23 at 3:54 PM logoAmphastar Pharmaceuticals Inc (AMPH) CEO & Chief Science Officer Jack Y. Zhang Sold $9.' million of Shares - (NASDAQ:AMPH) - September 23 at 8:18 AM logoAmphastar Pharmaceuticals Inc (AMPH) CEO & Chief Science Officer Jack Y. Zhang Sold $9. ... (NASDAQ:AMPH) - September 23 at 8:18 AM logoAmphastar Pharmaceuticals Inc. (AMPH) Rose To A New High After S&P Change (NASDAQ:AMPH) - September 21 at 4:23 PM logoAmphastar Pharmaceuticals Reaches Analyst Target Price (NASDAQ:AMPH) - September 21 at 4:23 PM
News IconWhy Amphastar Pharmaceuticals, Inc. is Soaring Today | Fox Business - Fox Business (NASDAQ:AMPH) - September 21 at 9:21 AM logo18 Biggest Mid-Day Gainers For Tuesday - Benzinga (NASDAQ:AMPH) - September 20 at 3:30 PM logoWhy Amphastar Pharmaceuticals, Inc. is Soaring Today - Motley Fool (NASDAQ:AMPH) - September 20 at 3:30 PM logoWhy Amphastar Pharmaceuticals, Inc. is Soaring Today (NASDAQ:AMPH) - September 20 at 3:29 PM logoStocks Higher Ahead Of Fed; Surging Biotechs Give Nasdaq A Boost (NASDAQ:AMPH) - September 20 at 3:29 PM logoTeva Presents Top-Line Data from Huntington Disease Study (NASDAQ:AMPH) - September 20 at 9:24 AM logoAmphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Brokerage Rating Update At 1.2 - Investor Newswire (NASDAQ:AMPH) - September 19 at 4:26 PM logoAmphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Posted A Surprise Factor Of 800 Percent - Investor Newswire (NASDAQ:AMPH) - September 17 at 3:29 PM
News IconAllergan paying $639 million for Vitae Pharmaceuticals (NASDAQ:AMPH) - September 16 at 12:10 PM
News IconAnalyst Projections and Growth Recap for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Post News (NASDAQ:AMPH) - September 15 at 8:38 PM
News IconAnalysts Take: Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Projected Earnings & Price Targets - Frisco Fastball (NASDAQ:AMPH) - September 13 at 3:29 PM
News IconPiper Jaffray Cos. Reiterates Overweight at Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH) - BNB Daily (blog) (NASDAQ:AMPH) - September 10 at 3:26 PM
News IconPlacing Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Under the Microscope - Post News (NASDAQ:AMPH) - September 9 at 3:27 PM
News IconStock Slipping Down Over the Past Five Trading Sessions: Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - National Daily Press (NASDAQ:AMPH) - September 9 at 3:27 PM logo5 Stocks with Favorable Liquidity Ratios for High Returns (NASDAQ:AMPH) - September 8 at 11:16 AM
News IconRhode Island, Amphastar extend Narcan rebate program (NASDAQ:AMPH) - September 7 at 8:37 PM
News IconHealth Workers Ration Opioid Overdose Antidote Amid Price Hikes (NASDAQ:AMPH) - September 6 at 8:35 PM


Amphastar Pharmaceuticals (NASDAQ:AMPH) Chart for Tuesday, October, 25, 2016

Last Updated on 10/25/2016 by Staff